Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this report , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report . 白云 山 廣州 白雲 山 医药 集团 股份有限公司 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO . , LTD . ( a joint stock company with limited liability established in the People's Republic of China ) ( H Share Stock Code : 0874 ) 1 . 2021 FIRST QUARTERLY REPORT IMPORTANT NOTICE 1.1 The board of directors ( the " Board " ) , the supervisory committee ( the “ Supervisory Committee ” ) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ( “ GYBYS ” or the " Company " ) and its directors , supervisors and senior management collectively and individually accept full responsibility for the truthfulness , accuracy and completeness of the information contained in this quarterly report and confirm that there are no false information , misleading statements or material omissions in this quarterly report . 1.2 The directors of the Company attended the 12th meeting of the eighth session of the Board , among whom , Mr. Li Hong ( an executive director and general manager ) , Mr. Wong Hin Wing ( an independent non - executive director ) , and Ms. Wang Weihong ( an independent non - executive director ) attended the meeting by telephone . 1.3 The financial reports of the Company and its subsidiaries ( collectively , the “ Group ” ) , and the Company for the first quarter ended 31 March 2021 ( the " Reporting Period ” ) were prepared in accordance with the China Accounting Standards for Business Enterprises , which were unaudited . 1.4 Mr. Li Chuyuan ( chairperson of the Board ) , Mr. Li Hong ( executive director and general manager ) and Ms. Yao Zhizhi ( deputy director of Finance and the head of finance department ) declared that they warranted that the financial reports contained in this quarterly report were true , accurate and complete . 1.5 This quarterly report is prepared in both English and Chinese . In the event that different interpretation occurs , the Chinese version shall prevail . -1-